Breaking News

ICON Appoints Analytics and Consulting VP

September 3, 2014

Spector brings 25 years of experience

Dr. Ira Spector has been appointed executive vice president, Analytics and Consulting, ICON plc. Dr. Spector will lead ICON’s global consulting and drug development services and will be responsible for business process improvement and analytics capabilities.
 
Dr. Spector has more than 25 years of experience in managing global drug and medical device development programs. He joins the company from Allergan Pharmaceuticals, where he was senior vice president of Global Development Operations, responsible for 11 global research centers, which contributed to approvals in more than 51 countries.
 
Dr. Spector previously spent 17 years at Wyeth Research, most recently as vice president, Global Development Operations and vice chief of Development, responsible for global clinical trial management.
 
Dr. Steve Cutler, chief operating officer at ICON, said, “I would like to welcome Dr. Spector to the ICON team. His extensive experience in managing some of the world’s largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers’ drug and device programs.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems